Usefulness of albumin-bilirubin grade for evaluation of prognosis of 2584 Japanese patients with hepatocellular carcinoma

被引:219
作者
Hiraoka, Atsushi [1 ]
Kumada, Takashi [3 ]
Michitaka, Kojiro [1 ]
Toyoda, Hidenori [3 ]
Tada, Toshifumi [3 ]
Ueki, Hidetaro [1 ]
Kaneto, Miho [1 ]
Aibiki, Toshihiko [1 ]
Okudaira, Tomonari [1 ]
Kawakami, Takamasa [1 ]
Kawamura, Tomoe [1 ]
Yamago, Hiroka [1 ]
Suga, Yoshifumi [1 ]
Miyamoto, Yuji [1 ]
Tomida, Hideomi [1 ]
Azemoto, Nobuaki [1 ]
Mori, Kenichiro [1 ]
Miyata, Hideki [1 ]
Ninomiya, Tomoyuki [1 ]
Kawasaki, Hideki [2 ]
机构
[1] Ehime Prefectural Cent Hosp, Gastroenterol Ctr, Kasuga Cho 83, Matsuyama, Ehime 7900024, Japan
[2] Ehime Prefectural Cent Hosp, Dept Surg, Kasuga Cho 83, Matsuyama, Ehime 7900024, Japan
[3] Ogaki Municipal Hosp, Dept Gastroenterol, Ogaki, Gifu, Japan
关键词
ALBI grade; hepatocellular carcinoma; JIS score; prognosis; scoring system; TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; CLINICAL-PRACTICE GUIDELINES; RADIOFREQUENCY ABLATION; NATIONWIDE SURVEY; STAGING SYSTEM; PHASE-3; TRIAL; HEPATITIS-C; CLIP SCORE; OPEN-LABEL; JIS SCORE;
D O I
10.1111/jgh.13250
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aim:The Child-Pugh classification has some non-objective factors, with chronic hepatitis indistinguishable from early liver cirrhosis in Child-Pugh A. We retrospectively evaluated the efficacy of albumin-bilirubin (ALBI) grade, which has been proposed as a new classification for hepatic function, for grading hepatocellular carcinoma (HCC) patients based on hepatic function and predicting their prognosis. Method:From 2000 to 2014, 2584 naive HCC [69.09.8years old, 1850 men, 734 female, Child-Pugh class A:B:C=1871:558:155] were enrolled. TNM staging was determined using the classification of the Liver Cancer Study Group of Japan and ALBI grade, instead of Child-Pugh classification (ALBI with TNM score: ALBI-T score) (Table1), and is similar to the Japan Integrated Staging (JIS) score. We retrospectively compared ALBI-T and JIS scores in these patients. Results:Of patients classified as Child-Pugh A (n=1871), 1285 with 5 points were divided into 858 with ALBI grade 1 and 427 with grade 2, while 586 with 6 points were divided into 53 with grade 1 and 533 with grade 2. The ratio of ALBI grade 2 patients with a Child-Pugh score of 6 points (91.0%) was similar to that of those with 7 points (91.8%). Patients with a lower ALBI-T score (0-5 points) showed a better median survival time than those with a corresponding lower JIS score [137.7:83.2:53.4:27.4:5.0:1.4 vs 97.6:74.9:39.7:15.0:4.0:1.0months]. Conclusion:Albumin-bilirubin grade was found to be superior for distinguishing patients with better hepatic function. ALBI-T scoring may be a better total prognostic scoring system for predicting survival of Japanese patients with HCC.
引用
收藏
页码:1031 / 1036
页数:6
相关论文
共 30 条
[1]   Etiology of non-B non-C hepatocellular carcinoma in the eastern district of Tokyo [J].
Abe, Hiroshi ;
Yoshizawa, Kai ;
Kitahara, Takuya ;
Aizawa, Ryoichi ;
Matsuoka, Mika ;
Aizawa, Yoshio .
JOURNAL OF GASTROENTEROLOGY, 2008, 43 (12) :967-974
[2]   A Risk for Hepatocellular Carcinoma Persists Long-term After Sustained Virologic Response in Patients With Hepatitis C-Associated Liver Cirrhosis [J].
Aleman, Soo ;
Rahbin, Nogol ;
Weiland, Ola ;
Davidsdottir, Loa ;
Hedenstierna, Magnus ;
Rose, Nina ;
Verbaan, Hans ;
Stal, Per ;
Carlsson, Tony ;
Norrgren, Hans ;
Ekbom, Anders ;
Granath, Fredrik ;
Hultcrantz, Rolf .
CLINICAL INFECTIOUS DISEASES, 2013, 57 (02) :230-236
[3]   Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan [J].
Arii, S ;
Yamaoka, Y ;
Futagawa, S ;
Inoue, K ;
Kobayashi, K ;
Kojiro, M ;
Makuuchi, M ;
Nakamura, Y ;
Okita, K ;
Yamada, R .
HEPATOLOGY, 2000, 32 (06) :1224-1229
[4]   Management of hepatoceullular carcinoma [J].
Bruix, J ;
Sherman, M .
HEPATOLOGY, 2005, 42 (05) :1208-1236
[5]   Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization [J].
Hiraoka, Atsushi ;
Ishimaru, Yoshihiro ;
Kawasaki, Hideki ;
Aibiki, Toshihiko ;
Okudaira, Tomonari ;
Toshimori, Akiko ;
Kawamura, Tomoe ;
Yamago, Hiroka ;
Nakahara, Hiromasa ;
Suga, Yoshifumi ;
Azemoto, Nobuaki ;
Miyata, Hideki ;
Miyamoto, Yasunao ;
Ninomiya, Tomoyuki ;
Hirooka, Masashi ;
Abe, Masanori ;
Matsuura, Bunzo ;
Hiasa, Yoichi ;
Michitaka, Kojiro .
ONCOLOGY, 2015, 89 (03) :167-174
[6]   Recent Trends of Japanese Hepatocellular Carcinoma due to HCV in Aging Society [J].
Hiraoka, Atsushi ;
Hidaka, Satoshi ;
Shimizu, Yuko ;
Utsunomiya, Hiroki ;
Imai, Yusuke ;
Tatsukawa, Haruka ;
Tazuya, Nayu ;
Yamago, Hiroka ;
Yorimitsu, Nobukazu ;
Tanihira, Tetsuya ;
Hasebe, Aki ;
Miyamoto, Yasunao ;
Ninomiya, Tomoyuki ;
Kawasaki, Hideki ;
Hirooka, Masashi ;
Abe, Masanori ;
Hiasa, Yoichi ;
Matsuura, Bunzo ;
Onji, Morikazu ;
Michitaka, Kojiro .
HEPATO-GASTROENTEROLOGY, 2012, 59 (118) :1893-1895
[7]   New contrast enhanced ultrasonography agent: Impact of Sonazoid on radiofrequency ablation [J].
Hiraoka, Atsushi ;
Hiasa, Yoichi ;
Onji, Morikazu ;
Michitaka, Kojiro .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2011, 26 (04) :616-618
[8]   Radiofrequency ablation therapy for hepatocellular carcinoma in elderly patients [J].
Hiraoka, Atsushi ;
Michitaka, Kojiro ;
Horiike, Norio ;
Hidaka, Satoshi ;
Uehara, Takahide ;
Ichikawa, Soichi ;
Hasebe, Aki ;
Miyamoto, Yasunao ;
Ninomiya, Tomoyuki ;
Sogabe, Ichiro ;
Ishimaru, Yoshihiro ;
Kawasaki, Hideki ;
Koizumi, Yohei ;
Hirooka, Masashi ;
Yamashita, Yoshimasa ;
Abe, Masanori ;
Hiasa, Yoichi ;
Matsuura, Bunzo ;
Onji, Morikazu .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2010, 25 (02) :403-407
[9]  
Hiraoka A, 2009, HEPATO-GASTROENTEROL, V56, P213
[10]   Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey [J].
Ikai, I ;
Arii, S ;
Kojiro, M ;
Ichida, T ;
Makuuchi, M ;
Matsuyama, Y ;
Nakanuma, Y ;
Okita, K ;
Omata, M ;
Takayasu, K ;
Yamaoka, Y .
CANCER, 2004, 101 (04) :796-802